[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054159":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":31,"locations":36,"responsibleParty":59,"collaborators":30,"id":61,"slug":30,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":30,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":30,"enrollmentInfo":69,"targetDuration":30,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":30,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"MBX Biosciences","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Canvuparatide","ACTIVE_COMPARATOR","Canvuparatide is provided as an integral drug-device combination product (DDC) intended for single-use administration, to deliver 1mL of canvuparatide via a manual SC injection. Dosing is once weekly.",[13],"Drug: Canvuparatide",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo is provided as an integral drug-device combination product (DDC) intended for single-use administration, to deliver 1mL of placebo via a manual SC injection. Dosing is once weekly.",[19],"Other: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","• Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg\u002FmL, 600 μg\u002FmL, 800 μg\u002FmL, 1000 μg\u002FmL, 1200 μg\u002FmL, 1400 μg\u002FmL, and 1600 μg\u002FmL.",[9],[26],"MBX 2109",{"type":28,"name":15,"description":23,"armGroupLabels":29,"otherNames":30},"OTHER",[15],null,[32],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":30},"Salomon Azoulay, MD","CONTACT","844-877-4473",[37,50],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":30},"MBX Biosciences Investigational Site","RECRUITING","Homestead","Florida","33030","United States",{"type":45,"coordinates":46},"Point",[47,48],-80.47756,25.46872,{"lat":48,"lon":47},{"facility":38,"status":39,"city":51,"state":52,"zip":53,"country":43,"cosmosGeoPoint":54,"geoPoint":58,"contacts":30},"Shavano Park","Texas","78231",{"type":45,"coordinates":55},[56,57],-98.55252,29.58495,{"lat":57,"lon":56},{"type":60,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100054159",false,"NCT07699471","A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism","Key Inclusion Criteria:\n\n1. Is an adult ≥18 years of age.\n2. Has a documented diagnosis of post-surgical, chronic HypoPT or genetic, idiopathic, or autoimmune HypoPT for at least 12 months prior to screening.\n3. Intact PTH level below the median value of the normal range\n4. Minimum requirement for a dose of calcitriol ≥0.5 μg\u002Fday, or alfacalcidol ≥1.0 μg\u002Fday and (elemental) calcium ≥1000 mg\u002Fday for at least 12 weeks prior to screening. In addition, the doses of calcitriol, or alfacalcidol, and calcium should be stable for at least 3 weeks prior to screening.\n5. Two (2) consecutive measurements of albumin-adjusted serum calcium at least 1 week apart within the range of 7.8 to 9.4 mg\u002FdL (1.95 to 2.35 mmol\u002FL).\n\nKey Exclusion Criteria:\n\n1. Has a known history of pseudohypoparathyroidism\n2. Clinically significant abnormal hematology, clinical chemistry, or coagulation.\n3. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HypoPT, such as active endogenous hyperthyroidism;\n4. Use of therapies affecting the calcium metabolism within 4 weeks prior to randomization\n5. PTH or PTH-related protein drugs such as PTH(1-84) and PTH(1-34) within 5 weeks prior to screening.","ALL","18 Years",{"count":70,"type":71},160,"ESTIMATED","INTERVENTIONAL",[74],"PHASE3","The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).",[77],"Hypoparathyroidism","2026-07-07",{"date":80,"type":81},"2026-07-13","ACTUAL",{"date":83,"type":71},"2026-08",{"date":85,"type":71},"2029-08",{"name":5,"class":6},2]